Shares of NewLink Genetics Corp (NASDAQ:NLNK) traded up 7.4% on Wednesday . The company traded as high as $9.23 and last traded at $9.10. 1,010,676 shares were traded during trading, an increase of 15% from the average session volume of 878,788 shares. The stock had previously closed at $8.47.
A number of analysts recently weighed in on the stock. BidaskClub upgraded shares of NewLink Genetics from a “sell” rating to a “hold” rating in a research note on Friday. Zacks Investment Research cut shares of NewLink Genetics from a “buy” rating to a “hold” rating in a research note on Thursday. ValuEngine cut shares of NewLink Genetics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 26th. Jefferies Group upgraded shares of NewLink Genetics from a “hold” rating to a “buy” rating and raised their target price for the stock from $7.00 to $26.00 in a research note on Friday, September 8th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $26.00 target price on shares of NewLink Genetics in a research note on Monday, September 25th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $23.29.
The company has a market cap of $364.39, a P/E ratio of -4.12 and a beta of 1.10.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.chaffeybreeze.com/2018/01/05/newlink-genetics-nlnk-trading-7-4-higher.html.
NewLink Genetics Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.